Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 19;11(7):605-609.
doi: 10.1093/jmcb/mjz067.

Gain-of-function mutant p53: history and speculation

Jill Bargonetti  1 , Carol Prives  2
Affiliations
Review

Gain-of-function mutant p53: history and speculation

Jill Bargonetti et al. J Mol Cell Biol. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Domain organization of the p53 protein. The domain boundaries corresponding to human p53 protein are shown with amino acid numbers at bottom. The red outlined boxes show transcription activation domains 1 and 2 (AD1, AD2); the brown outlined box indicates the PR domain; the purple outlined box corresponds to the site-specific DNA binding domain; the non-specific DNA binding carboxyl terminal region comprises the green outlined box that indicates the OD followed by the yellow outlined box containing the lysine-rich 6 K region (CTD). The full sequence of the CTD is shown with the six lysine residues in red and listed below. The GOF missense mutations at R175, R248, and R273 are indicated on top of the purple outlined site-specific DNA binding domain. Listed below are some of the key functions that AD1 and AD2 on the left and CTD on the right are known to promote.
Figure 2
Figure 2
Carol Prives, Jill Bargonetti, and Arnold Levine at the 2014 Cold Spring Harbor Laboratories Meeting: Mechanisms and Models of Cancer.
See this image and copyright information in PMC

References

    1. Aschauer L., and Muller P.A. (2016). Novel targets and interaction partners of mutant p53 gain-of-function. Biochem. Soc. Trans. 44, 460–466. - PubMed
    1. Baker S.J., Fearon E.R., Nigro J.M., et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 244, 217–221. - PubMed
    1. Bargonetti J., Friedman P.N., Kern S.E., et al. (1991). Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65, 1083–1091. - PubMed
    1. Bayle J.H., Elenbaas B., and Levine A.J. (1995). The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl Acad. Sci. USA 92, 5729–5733. - PMC - PubMed
    1. Bellazzo A., Sicari D., Valentino E., et al. (2018). Complexes formed by mutant p53 and their roles in breast cancer. Breast Cancer 10, 101–112. - PMC - PubMed

Publication types

MeSH terms

Substances